HVIVO - Key Persons

Job Titles:

• VP, Clinical Operations

Adam brings over 18 years' experience working in a number of roles in the Pharmaceutical and CRO industry, including project management and laboratory leadership. His love for biological sciences started from a young age and was cemented after graduating from Anglia Ruskin University in Biomedical Sciences whilst working in the labs at Huntingdon Life Sciences. There his skills for operational leadership were honed whilst working on global business change and strategy projects, before he moved on to more senior roles elsewhere. Adam joined hVIVO in 2014, where he has implemented a number of productivity and growth improvements, with a focus on operational delivery, business growth and personnel development.

Job Titles:

• Chief Scientific Officer

Andrew first studied as a virologist at the University of Warwick before then furthering his education with postgraduate studies in influenza replication at Oxford University. Since then he has applied his scientific knowledge in a commercial setting. After working as part of a multidisciplinary R&D team developing nuclear medicine research tools at GE Healthcare, he then returned to the field of virology to work for hVIVO, an industry-leading service provider of human viral challenge studies (controlled human infection studies). Andrew is now considered an expert in human viral challenge studies having played key roles in the development of influenza, RSV and HRV models at hVIVO. He has overseen the design and conduct of numerous antiviral and vaccine product efficacy studies and now works as Chief Scientific Officer, leading scientific strategy for the company as well as providing consultancy both internally and externally to hVIVO's clients and collaborators on challenge study design and data interpretation. In addition, he was PI on a recent successfully completed DARPA-sponsored research project to utilise the challenge model to identity human biomarkers and algorithms prognostic of influenza contagiousness.

Job Titles:

• Member of the Audit Committee
• Member of the Board of Directors
• Non - Executive Director

Brendan Buckley, the Non-Executive Director chairs the Remuneration Committee and is a member of the Audit Committee and the Risk Committee. Brendan was Chief Medical Officer of ICON plc until 2017, prior to which he co-founded Firecrest Clinical, a company which focused on improving the performance of clinical trial sites and in turn sold it ICON in 2011. While in ICON Brendan served as a member of ICON plc's Executive Leadership Team and was actively involved in M&A targeting, assessment and diligence. A medical graduate of University College Cork (UCC) and a doctoral graduate in Biochemistry of Oxford University, Brendan has over 30 years' experience in clinical research. He was a Director of the Health Products Regulatory Authority of Ireland between 2004 and 2011 and was a member of the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) from 2000-2003.

Job Titles:

• VP, Regulatory Affairs

Bruno brings a wealth of drug development and regulatory strategy experience to hVIVO (formerly Open Orphan). He has an extensive expertise in supporting global drug development programs and guiding biotech / pharma companies in their interactions with global regulators, including EMA & FDA. He is currently advising a broad range of organisations (non-profits, biotechs, large pharma) on the regulatory aspects of their drug/vaccine development, from early development to commercialisation stage. Before joining hVIVO, Bruno had a variety of roles at SGS Life Sciences, where in his last position he managed the global regulatory consultancy and modelling & simulation teams. Bruno is a bio-engineer in cel- & genetechnology from the University of Ghent in Belgium, and holds a postgraduate degree in Health Economics (EHSAL Management School, Belgium).

Job Titles:

• Chairman
• Chairman of the Board of Directors
• Non - Executive Chairman

Cathal is 56 years-old, and is an entrepreneur, starting work at 16 years due to his father's untimely illness he went on to complete his education at night classes and got an MBA from the University of Ulster in 1990. He spent the following five years lecturing part time in International Marketing and Business Planning at the University of Ulster, while running his own new technology services business. In 2001 he was part of the team who successfully established Merrion Stockbrokers in Dublin and in 2007 he founded Raglan Capital. Cathal is the Executive Chairman and Co-Founder of hVIVO (formerly Open Orphan plc) which IPO'd on the London and Dublin stock exchanges in June 2019. In 2021, hVIVO (formerly Open Orphan) completed a spin-out of one of its non-core assets to form Poolbeg Pharma plc, an infectious disease company with a capital light model, where Cathal is Chairman. He also co-founded Amryt Pharma plc in 2015 along with Joe Wiley, which is listed on the London stock exchange since 2016 and which listed on Nasdaq in July 2020. Prior to Amryt, Cathal founded Fastnet Oil & Gas plc in 2011 which he IPO'd on the London stock exchange. Cathal was a finalist in the International category as part of the EY Entrepreneur of the Year 2020. Cathal Friel, the Non-Executive Chairman has the responsibility for ensuring that the Board discharges its responsibilities and is also responsible for facilitating full and constructive contributions from each member of the Board in determining the Group's strategy and overall commercial objectives.

Job Titles:

• Independent Non - Executive Director
• Member of the Board of Directors
• Member of the Remuneration Committee
• Non - Executive Director
• CEO of Dargle Therapeutics
• Independent Non - Executive Director, Appointed to the Board in November 2020
• Members of the Audit and Risk Committee

Elaine Sullivan, an Independent Non-Executive Director is Chair of the Nomination Committee. Elaine is a member of the Remuneration Committee and Audit & Risk Committee. Elaine is CEO of Dargle Therapeutics, the Executive Chairman of Keltic Pharma and a Non-Executive Director at hVIVO (formerly Open Orphan), IP Group plc and Active Biotech AB and is a member of the Supervisory Board at Evotec AG which is listed on the Frankfurt Stock Exchange. She has over 25 years of international experience working in the pharmaceutical and biotech industry. Elaine has worked as part of the most senior management teams in R&D at Eli Lilly and AstraZeneca. She served as Vice President Global External Research and Development at Eli Lilly & Company, Inc., Indianapolis, USA, where she led a global workforce delivering access to business-critical external innovation. She was a member of the investment committees of Lilly Ventures and Lilly Asian Ventures and the steering committees of Lilly's Capital Fund partners. Prior to joining Eli Lilly, Dr Sullivan held various positions in the area of drug discovery and development at AstraZeneca including Vice President R&D, New Opportunities. In this role, she led AstraZeneca‘s virtual therapy disease function which pinpointed new disease areas and created new therapeutic applications for multiple molecular entities and advanced them into the clinic. She also held the role of Vice-President, Science & Technology with the focus on acquiring new technologies which led to decreased attrition of compounds failing for toxicity and efficacy reasons in the clinic. During her career, she gained extensive knowledge of various aspects of drug discovery and development having developed new molecules in virology, cancer and ophthalmology. She co-founded Carrick Therapeutics a European oncology company which has raised 100 million. She has successfully delivered over 250 collaborations and transactions including spinouts, joint ventures, strategic partnerships and acquisitions. Dr Sullivan holds a doctorate in Molecular Biology and Virology from the University of Edinburgh, UK, and a bachelor's degree in Molecular Biology from the University of Glasgow, UK.

Job Titles:

• Medical Director

Mariya has worked for hVIVO since 2014 in various roles including Viral Challenge Physician, Senior Physician/ Principal Investigator, Associate Medical Director and has been appointed in March 2021 as Medical Director. Since qualification in 1996 at the Medical University, Sofia, Bulgaria Mariya specialized in General (Internal) Medicine. Mariya have wide experience in oncology, hematology, rheumatology, gastroenterology, endocrinology and Chronic & Preventative Care; both in Bulgaria and the UK. She is on the GMC Specialist Register for General (Internal) Medicine, and has a current ALS certificate. Mariya is an experienced pharmaceutical physician; this expertise extends to RSV challenges, Influenza, HRV and SARS-CoV-2. As PI, Mariya has been responsible for many clinical trials including RSV, SARS-CoV-2 characterisation and vaccine trials. She has developed and overseen clinical development for clients including safety and medical monitoring. She also regularly trains, supervises and supports staff and investigators.

Job Titles:

• Chairman of the Audit & Risk Committee
• Independent Non - Executive Director
• Member of the Board of Directors
• Member of the Remuneration Committee
• Independent Non - Executive Director, Appointed to the Board in June 2022
• Members of the Committee
• Members of the Remuneration Committee

The Executive Directors are expected to devote substantially the whole of their time to their duties with the Company. The Board meets formally eight times a year with ad hoc Board meetings as the business demands. There is a strong flow of communication between the Directors. The Board has not undertaken any formal training during the year. This will continue to be monitored. Principle Six: Ensure that between them the Directors have the necessary up to date experience, skills and capabilities Martin Gouldstone, an Independent Non-Executive Director is Chair of the Audit & Risk Committee and is a member of the Remuneration Committee and Nomination Committee. The Audit and Risk Committee comprises Martin Gouldstone as Chairperson with Brendan Buckley and Elaine Sullivan as the other members of the Audit and Risk Committee and meets at least twice a year. The principal duties of the Audit and Risk Committee are to review the half-yearly and annual financial statements before their submission to the Board and to consider any matters raised by the auditors. The Audit and Risk Committee also reviews the independence and objectivity of the auditors. The terms of reference of the Audit and Risk Committee reflect current best practice, including authority to: recommend the appointment, re-appointment and removal of the external auditors; ensure the objectivity and independence of the auditors including occasions when non-audit services are provided; and ensure appropriate ‘whistle-blowing' arrangements are in place. Martin brings 30 years corporate finance and development experience in the CRO, healthcare and pharmaceutical sectors to hVIVO (formerly Open Orphan). Martin is Global SVP, Business Development at Owkin. He was previously a Partner at Results Healthcare, where he co-led the healthcare practice. He was Head of Lifesciences in the UK for BDO, the Lead for the M&A process in Europe for Quintiles, and Business Development and Licensing Lead at Confirmant, Pharmacopeia, Sareum and CBO at BenevolentAI and Sensyne Health. He has extensive experience buying and selling multi-billion dollar deals across Europe and the US, architecting end to end portfolio out-sourcing deals, and negotiating multi-year research partnerships. He holds a BSc in Genetics and has completed a range of post graduate management courses.

Job Titles:

• Chief Financial Officer
• Member of the Board of Directors

Stephen Pinkerton, the Chief Financial Officer is responsible for shaping and executing the financial strategy and operational direction of the Company, as well as the overall financial reporting and compliance requirements of the Company. Stephen Pinkerton is Chief Financial Officer at hVIVO. Having worked at the company for six years, he has developed a strong end to end understanding of the business, working across all key commercial operational decisions. During his time at the company, he helped transform the financial reporting, monthly accounts and forecasting of the business, overhauled the project accounting system, developed pricing models for all the contracts that range in value from £2m to £15m, improved pricing and margin on contracts, oversaw forecast models for mergers, acquisitions and operational performance, and supported on the restructuring of the business to improve efficiencies. Stephen has an extensive career in a range of leadership positions. Prior to joining hVIVO, he worked in Thomson Reuters for eleven years, most recently as Finance Director for Enterprise Risk Management. He holds a Honours Degree in Bachelor of Commerce and a Bachelor's Degree in Accounting and Finance from the University of Cape Town.

Teja brings 12 years' experience of working in a number of QA GCP roles in the Clinical research & CRO industry. She has extensive experience in conducting GCP & GCLP audits, supplier audits and hosting external inspections. She has led multiple projects involving improvement of existing processes and systems, implementation of GCP compliant standards within business and regulatory gap analysis. She has worked at hVIVO since 2016 and was appointed as Head of QA in 2021. Previously she worked as a GCP Compliance manager at Institute of Cancer Research/Royal Marsden Hospital. Teja is a pharmacist and holds M. Tech degree in Bioprocess Technology and Doctorate degree in Pharmaceutical Sciences from University of Mumbai, India.

Job Titles:

• Chief Executive Officer
• Member of the Board of Directors

Yamin ‘Mo' Khan, as the Chief Executive Officer is responsible for business execution within the framework and structures defined by the Board. He engages with shareholders and other stakeholder groups to ensure a strong relationship between them and the Company.